7 completed, 2 unknown. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 7, Unknown 2 |
Follow pegvisomant: new trials by email Literature Review of pegvisomant trials Research Report on pegvisomant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pasireotide LAR and Pegvisomant Study in Acromegaly Pasireotide LAR 60 mg, Pegvisomant - Acromegaly | Phase 4 | Unknown | Erasmus Medical Center | 60 | 2015-08-01 | 2016-08-03 |
| Effect of DPP4 Inhibition on Growth Hormone Secretion Sitagliptin, Pegvisomant, Placebo - Obesity | Phase 4 | Completed | Vanderbilt University | 44 | 2013-01-01 | 2018-05-29 |
| Acute Application of Pegvisomant and Octreotide in Acromegaly pegvisomant, combination with somatostatin analogue octreotide, combination with dopamine agonist cabergoline - Acromegaly | Phase 4 | Completed | Ludwig-Maximilians - University of Munich | 10 | 2008-01-01 | 2008-04-01 |
| Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Pegvisomant - Quality of Life, Acromegaly | Phase 4 | Completed | Erasmus Medical Center | 20 | 2006-10-01 | 2008-03-25 |
| Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Sandostatin LAR, pegvisomant, cabergoline - Acromegaly | Phase 4 | Completed | Novartis Pharmaceuticals | 70 | 2006-09-01 | 2017-03-03 |
| Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant pegvisomant - Acromegaly, Heart Failure | Phase 4 | Unknown | University of Wuerzburg | 4 | 2006-06-01 | 2010-09-24 |
| Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Octreotide acetate and cabergoline/Octrotide and Somavert - Acromegaly | Phase 4 | Completed | Novartis Pharmaceuticals | 20 | 2006-03-01 | 2017-03-06 |
| Pegvisomant And Sandostatin LAR Combination Study Pegvisomant/ Sandostatin LAR, Sandostatin LAR, Pegvisomant - Acromegaly | Phase 4 | Completed | Pfizer | 75 | 2003-10-01 | 2008-04-07 |
| A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Pegvisomant, Sandostatin LAR - Acromegaly | Phase 4 | Completed | Pfizer | 100 | 2003-04-01 | 2008-04-07 |
Acromegaly (8) · Brain Neoplasms (1) · Cardiomegaly (1) · Heart Failure (1) · Hypertrophy (1) · Hypertrophy, Left Ventricular (1) · Obesity (1) · Pituitary Neoplasms (1)
Erasmus Medical Center (2) · Novartis Pharmaceuticals (2) · Pfizer (2) · Ludwig-Maximilians - University of Munich (1) · University of Wuerzburg (1) · Vanderbilt University (1)
Germany (5) · France (3) · Italy (3) · United States (3) · Australia (2) · Brazil (2) · Canada (2) · Netherlands (2) · Norway (2) · Spain (2) · United Kingdom (2) · Greece (1) · Ireland (1) · Mexico (1) · Poland (1)
Bruno Allolio, MD (1) · Jessica K Devin, MD, MSCI (1) · Jochen Schopohl, MD (1) · Sebastian Neggers, MD PhD (1)
2005 (1), 2014 (1), K23HL119602 (1)